Morgan Stanley Cellectar Biosciences, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	SELL	$3.5 - $6.9 $10 - $20	-3 Reduced 13.64%	19 $0
Q2 2022 Aug 15, 2022	SELL	$3.5 - $6.9 $10 - $20	-3 Reduced 13.64%	19 $0
Q1 2022 Oct 27, 2022	BUY	$4.6 - $7.8 $13 - $23	3 Added 15.79%	22 $0
Q1 2022 May 13, 2022	SELL	$4.6 - $7.8 $1.27 Million - $2.16 Million	-276,954 Reduced 99.99%	22 $0
Q4 2021 Feb 14, 2022	SELL	$6.1 - $10.2 $1.84 Million - $3.07 Million	-301,385 Reduced 52.11%	276,976 $184,000
Q3 2021 Nov 15, 2021	BUY	$8.2 - $12.4 $4.74 Million - $7.17 Million	578,361 New	578,361 $535,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $9.6M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.